Celldex reports Q2 2021 net loss of $13.4M; raises $287.5M in follow-on offering

Celldex Therapeutics, Inc.

2022-Q2 EPS reported -$0.76 revenue$4,165,000

Net loss $13.4M ($0.34/share) vs $11.0M ($0.50/share) in Q2 2020; revenue $3.5M vs $0.2M.
Cash $164.0M at June 30, 2021; July follow-on offering added $287.5M gross ($270M net), extending runway through 2025.
CDX-0159 Phase 1b: 95% complete response in chronic inducible urticaria; 87% skin mast cell depletion with single dose.
Plan to initiate CDX-0159 study in prurigo nodularis in Q4 2021 and subcutaneous formulation Phase 1 in Q3 2021.
CDX-1140 expansion cohorts recruiting; CDX-527 dose escalation completed, expansion cohorts planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.